1 / 8

ECLIPSE Trial: E nsure’s Vas c ular C l osure Dev i ce S p eed s H e mostasis

ECLIPSE Trial: E nsure’s Vas c ular C l osure Dev i ce S p eed s H e mostasis. S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian Hosp.- Cornell Campus Professor of Medicine Weill Medical College of Cornell University.

doctor
Download Presentation

ECLIPSE Trial: E nsure’s Vas c ular C l osure Dev i ce S p eed s H e mostasis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian Hosp.- Cornell Campus Professor of Medicine Weill Medical College of Cornell University SCAI / ACCi2 2008 Late Breaking TrialApril 2nd Chicago, IL

  2. ECLIPSE TrialEclipse® Closure Device • The investigational ExoSeal device (Cordis, Miami FL) is a novel 3rd generation 6 Fr. extra-vascular closure device with a painless deployment mechanism that delivers a poly-glycolic acid (PGA) “felt-like” plug atop the femoral artery anchored by the neuro-vascular bundle sheath.

  3. ECLIPSE Trial ECLIPSE Trial Design • U.S. multicenter pivotal study comparing ExoSeal and manual compression with 2:1 randomization was performed to assess the safety and efficacy of ExoSeal in patients undergoing 6Fr. diagnostic and interventional coronary/peripheral procedures

  4. ECLIPSE Trial Objectives • Two primary effectiveness endpoints to be tested for superiority: • Time to hemostasis (TTH) • Time to ambulation (TTA) • Primary safety endpoint to be tested for non-inferiority: • 30-day combined rate of access site related complications including bleeding, infection, ischemia or injury requiring medical or surgical treatment

  5. ECLIPSE Trial Patient Enrollment ExoSeal® 6F VCD (17 U.S. Sites)N = 488 Roll-in N = 87 Withdrawn N = 5 (2.7%) Randomized N = 401 30 day FU N = 82 (94.3%) ExoSeal® (N=267) Mannual Compression (n=134) Withdrawn N = 14 (5.2%) Withdrawn N = 10 (7.5%) 30-day FU N=253 ( 94.8%) 30-day FU N=124 (92.5%)

  6. ECLIPSE Trial Results: Primary Effectiveness Endpoints

  7. ECLIPSE Trial Results: Primary 30-Day Safety Endpoints zero!

  8. ECLIPSE Trial Conclusions • In this multi-center randomized trial in pts following 6 Fr. diagnostic/interventional procedures, a significant reduction in the TTH and TTA (primary effectiveness endpoints) was achieved in pts treated with the investigational ExoSeal device compared with MC • Device deployment was achieved promptly in about 1 minute on average following procedure • There was no difference in procedural success rates in both the ExoSeal® and MC groups • Remarkably, there were no30-day combined access site related complications (primary safety endpoint) reported in either treatment cohort • Exoseal is non-inferior to MC in composite major adverse event at the pre-specified 4% margin level • Exoseal®compares favorably to manual compression for arteriotomy site management post 6 Fr. invasive/interventional procedures.

More Related